Dr. Tina Tianning Yu is the Chief Executive Officer and President of Mevion Medical Systems, the leader in compact proton therapy. With over 20 years of experience in life sciences, healthcare, and finance, Dr. Yu brings a unique blend of scientific expertise and business acumen to advancing cancer care.
Prior to Mevion, she was a Co-Founding Partner of YuanMing Capital, leading investments in successful biotech companies, including BeiGene and Ascentage Pharmaceuticals. Her career includes financial experience at institutions such as Vision Capital, Fidelity Asia Ventures, Morgan Stanley and Genzyme Biopharma, as well as scientific positions at Wyeth BioPharma.
Under Dr. Yu’s leadership, Mevion has achieved significant global growth and strong financial performance, becoming the preferred proton therapy provider for more NCI-Designated Comprehensive Cancer Centers. She led the development of the groundbreaking MEVION S250-FIT, the first proton therapy system designed for existing LINAC vaults. This system significantly reduces proton therapy’s size and complexity, enabling any health systems to bring proton therapy and benefit more patients.
Dr. Yu is a member of the CEOs Against Cancer – New England Chapter and was named to the Worcester Business Journal’s “Power 50” list. She is also a Regional Director with the Harvard Business School Healthcare Alumni Association. She holds a Ph.D. in Chemistry from Princeton, an MBA from Harvard, and a B.S. in Biology from the University of Science
and Technology of China.